1 domain / 2 areas / 1 specialization
OMX Venture
Data updated
OMX Ventures is a venture capital firm based in Chicago, Illinois, focused on bioengineering and life sciences investing. Its public materials describe a technology-first approach centered on early-stage companies working across biology, big data, AI, therapeutics, bio tools, diagnostics, and synthetic biology.
In the psychedelic ecosystem, OMX matters because it is a founding investor in Delix Therapeutics, a company developing non-hallucinogenic versions of psychedelic compounds for psychiatric and neurological indications. OMX has also publicly participated in other drug-development and biotech rounds, suggesting a broader interest in therapeutics that overlap with psychedelic-adjacent neuroscience.
Investor Context
Venture CapitalInvestment Context
This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.
Public Portfolio Examples
- Delix TherapeuticsSeries A - $70 million - Sep 27, 2021
OMX Ventures appears to invest early in platform-driven biotech and therapeutics companies, with a stated emphasis on building and supporting companies through their first years of operations. Its relevance to psychedelics is mainly through Delix Therapeutics, where OMX is named as a founding investor and continued backer of non-hallucinogenic psychoplastogen development, aligning it with the psychedelic-adjacent drug development segment rather than direct plant-medicine or clinic operations.
Investor Type
Venture Capital Fund
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Recorded Investments
Sep 27, 2021
Series A - $70 million
OMX was named a founding investor in a round that explicitly included life sciences and psychedelic investment funds.
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain DisordersQuick Facts
- Founded
- 2020
- HQ
- Chicago, IL, United States
- Website
- Visit